Claudin 18.2 as a novel therapeutic target
#5PRI RANKED
Most Cited Paper
in Cancer-related molecular mechanisms research
18 Months Post-Publication
Class of 2026
“Claudin 18.2 as a novel therapeutic target”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/cancer-related-molecular-mechanisms-research/2026/
Topics
CLDN18.2 · CLDN18.2 · Therapeutic target · gastric cancer · pancreatic cancer · tight junction protein · zolbetuximab · monoclonal antibody therapy · tumor-associated antigen · antibody-drug conjugate · CAR-T cell therapy · Cancer immunotherapy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related molecular mechanisms research Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-mechanisms-research/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459